Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The senescence-associated secretome of Hedgehog-deficient hepatocytes drives MASLD progression
Ji Hye Jun, … , Steven S. Pullen, Anna Mae Diehl
Ji Hye Jun, … , Steven S. Pullen, Anna Mae Diehl
Published August 27, 2024
Citation Information: J Clin Invest. 2024;134(19):e180310. https://doi.org/10.1172/JCI180310.
View: Text | PDF
Research Article Hepatology Metabolism

The senescence-associated secretome of Hedgehog-deficient hepatocytes drives MASLD progression

  • Text
  • PDF
Abstract

The burden of senescent hepatocytes correlates with the severity of metabolic dysfunction–associated steatotic liver disease (MASLD), but the mechanisms driving senescence and how it exacerbates MASLD are poorly understood. Hepatocytes experience lipotoxicity and become senescent when Smoothened (Smo) is deleted to disrupt Hedgehog signaling. We aimed to determine whether the secretomes of Smo-deficient hepatocytes perpetuate senescence to drive MASLD progression. RNA-Seq analysis of liver samples from human and murine cohorts with MASLD confirmed that hepatocyte populations in MASLD livers were depleted of Smo+ cells and enriched with senescent cells. When fed a choline-deficient, amino acid–restricted high-fat diet (CDA-HFD) to induce MASLD, Smo– mice had lower antioxidant markers and developed worse DNA damage, senescence, steatohepatitis, and fibrosis than did Smo+ mice. Sera and hepatocyte-conditioned medium from Smo– mice were depleted of thymidine phosphorylase (TP), a protein that maintains mitochondrial fitness. Treating Smo– hepatocytes with TP reduced senescence and lipotoxicity, whereas inhibiting TP in Smo+ hepatocytes had the opposite effect and exacerbated hepatocyte senescence, steatohepatitis, and fibrosis in CDA-HFD–fed mice. We conclude that inhibition of Hedgehog signaling in hepatocytes promoted MASLD by suppressing hepatocyte production of proteins that prevent lipotoxicity and senescence.

Authors

Ji Hye Jun, Kuo Du, Rajesh Kumar Dutta, Raquel Maeso-Diaz, Seh Hoon Oh, Liuyang Wang, Guannan Gao, Ana Ferreira, Jon Hill, Steven S. Pullen, Anna Mae Diehl

×

Figure 5

Inhibiting TP exacerbates diet-induced MASH and liver fibrosis in WT mice.

Options: View larger image (or click on image) Download as PowerPoint
Inhibiting TP exacerbates diet-induced MASH and liver fibrosis in WT mic...
(A) WT mice were fed a CDA-HFD diet for 6 weeks and were intraperitoneally injected with a TPI (tipiracil-HCl) or its vehicle 3 times. (B) Liver/body weight ratio in TPI-treated versus vehicle-treated mice (n = 10 mice per group). (C) Representative images of staining for H&E, Oil Red O, Picrosirius red, F480, β-gal and corresponding densitometric analysis of positively stained areas. Scale bars: 100 μm (H&E-, F480-, and Picrosirius red–stained images) and 50 μm (Oil Red O– and β-gal–stained images). Serological results of hepatic function markers (D) ALT and AST and (E) HOMA-IR (n = 10 mice per group). (F) Expression of the senescence markers p16 and p21 detected in total liver from TPI-treated mice, as detected by immunoblotting (n = 7 mice per group). (G) Concentration of TP in serum from vehicle- and TPI-treated mice (n = 10 mice per group). (H) Protein expressions of TP, Smo, Nrf2, and HO1 detected in total liver from TPI-treated mice, as detected by immunoblotting (n = 7 mice per groups). (I) Expression of the mitochondrial OXPHOS complex markers NDUFB8 and ATP5A detected in total liver mitochondria from vehicle- or TPI-treated mice, as detected by immunoblotting (n = 7 mice per group). Data are graphed as the mean ± SEM. *P < 0.05, by 1-way ANOVA.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts